Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Up 42.1% in August

Key Points

• Cellebrite DI Ltd. experienced a significant increase in short interest, rising by 42.1% in August to 5,160,000 shares.
• The company reported earnings per share (EPS) of $0.12 for the quarter, exceeding estimates, while revenue was up 18.4% year-over-year, totaling $113.28 million.
• Brokerages have varied outlooks on CBLT, with five analysts rating the stock as Buy and an average price target of $22.40.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totaling 5,160,000 shares, anincreaseof42.1% from the July 31st total of 3,630,000 shares. Approximately4.7% of the shares of the company are short sold. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is currently 2.9 days. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is currently 2.9 days. Approximately4.7% of the shares of the company are short sold.

Cellebrite DI Price Performance

CLBT stock traded up $0.48 during midday trading on Monday, hitting $17.09. 2,384,044 shares of the stock traded hands, compared to its average volume of 1,699,642. The firm has a market cap of $4.09 billion, a P/E ratio of -22.49, a PEG ratio of 3.02 and a beta of 1.28. The stock's fifty day simple moving average is $15.03 and its 200-day simple moving average is $17.01. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Cellebrite DI will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently added to or reduced their stakes in the business. Signaturefd LLC increased its position in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company's stock valued at $32,000 after purchasing an additional 819 shares during the last quarter. Assetmark Inc. purchased a new position in shares of Cellebrite DI in the 1st quarter valued at $33,000. PNC Financial Services Group Inc. boosted its stake in Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company's stock worth $34,000 after purchasing an additional 1,998 shares during the period. Catalyst Capital Advisors LLC acquired a new stake in shares of Cellebrite DI in the 1st quarter worth $51,000. Finally, Virtus Advisers LLC acquired a new stake in shares of Cellebrite DI in the 1st quarter worth $63,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CLBT. Wall Street Zen raised Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. JPMorgan Chase & Co. cut their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Finally, Lake Street Capital lowered their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $22.40.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.